Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

ClinicalTrials.gov ID: NCT07531095

Public ClinicalTrials.gov record NCT07531095. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With ZL-1310 With or Without Anti-PD-L1 in Participants With Small Cell Lung Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.

Study identification

NCT ID: NCT07531095
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Amgen; Industry
Enrollment: 160 participants

Conditions and interventions

Conditions

Small Cell Lung Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 21, 2026 (Actual)
Primary completion: May 21, 2028 (Estimated)
Completion: May 21, 2031 (Estimated)
Last update posted: Aug 21, 2026

2026 – 2031

United States locations

U.S. sites: 7
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
City of Hope Cancer Center Phoenix	Goodyear	Arizona	85338	Recruiting
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
City of Hope Chicago	Zion	Illinois	60099	Recruiting
Health Partners Cancer Center at Regions Hospital	Saint Paul	Minnesota	55101	Recruiting
New York University Cancer Institute	New York	New York	10016	Recruiting
Baptist Cancer Center	Memphis	Tennessee	38120	Recruiting
Next Virginia	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07531095, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 21, 2026 · Synced Oct 20, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07531095 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →